

VIRTUAL CONFERENCE · 23-24 NOVEMBER 2021

FORMERLY THE BIOMARKER MEETING OF PARIS

BIOMARKERS

of the Future

FROM BEDSIDE TO PRACTICE

PRELIMINARY SCIENTIFIC PROGRAMME

SCIENTIFIC COMMITTEE

PIERRE-FRANÇOIS LATERRE
University of Louvain - Brussels, Belgium

ALEXANDRE MEBAZAA
University of Paris - Paris, France

JANE-LISE SAMUEL
University of Paris - Paris, France

KAREN SLIWA-HAHNLE
University of Cape Town - Cape Town, South Africa



TUESDAY, 23 NOVEMBER 2021

FORMERLY THE BIOMARKER MEETING OF PARIS
BIOMARKERS
of the Future



INTRODUCTION & WELCOME MESSAGE BY SCIENTIFIC COMMITTEE



SESSION 1 - UNMET AND URGENT NEEDS IN MEDICINE

Moderator: Jane-Lise Samuel - University of Paris (Paris, France)

Cardiovascular diseases in LMCs

Karen Sliwa-Hahnle - University of Cape Town

Cape Town, South Africa

Critical care

Pierre-François Laterre - University of Louvain

Brussels, Belgium

Cardiogenic Shock: a deadly disease

Alexandre Mebazaa - University of Paris

Paris, France

Panel discussion

Break



SESSION 2 - WOMEN AND CARDIOVASCULAR DISEASE

Moderator: Jane-Lise Samuel - University of Paris (Paris, France)

HT disorders of pregnancies and long-term implications

Karen Sliwa-Hahnle - University of Cape Town

Cape Town, South Africa

Reducing the global burden by 2030

Roxana Mehran - Icahn School of Medicine at Mount Sinai New York City, United States

TUESDAY, 23 NOVEMBER 2021 (CONTINUED)



05:24 AM
NYC (UTC-5)



11:24
PARIS (UTC+1)



18:24
SINGAPORE (UTC+8)



21:24
SYDNEY (UTC+11)

SESSION 3 - NOVELTIES IN THE BIOMARKERS OF THE FUTURE

Moderator: Camille Chenevier-Gobeaux - Hopital Cochin (Paris, France)

Traumatic Brain Injury biomarkers - from discovery to recent FDA clearance of first Point-of-Care blood test
Kevin Wang - McKnight Brain Institute, University of Florida Gainesville, USA

Proteomics in clinical practice
Joachim Beige - Hospital St. Georg

Leipzig, Germany

AI and biomarker analysis
Nicolas Girerd - University of Lorraine

Nancy, France

Novel paths for inflammation
Benjamin Chousterman - Hopital Lariboisière

Paris, France

Panel discussion

Break



08:00 AM
NYC (UTC-5)



14:00
PARIS (UTC+1)



21:00
SINGAPORE (UTC+8)



00:00 (WED)
SYDNEY (UTC+11)

SESSION 4 - BIOMARKERS ARE EAGERLY NEEDED

Moderator: Etienne Gayat - Hopital Lariboisière (Paris, France)

Biomarkers are eagerly needed to reduce the global burden of cardiovascular disease in women
Birgit Vogel - Mount Sinai Morningside New York City, United States

Biomarkers are eagerly needed in Cardio-oncology
Alain Cohen-Solal - University of Paris

Paris, France

Biomarkers are eagerly needed in my practice
Javed Butler - University of Mississippi

Jackson, United States

Biomarkers are eagerly needed in my research
Christopher Defilippi - Inova Heart and Vascular Institute

Baltimore, United States

Panel discussion



09:30 AM
NYC (UTC-5)



15:30
PARIS (UTC+1)



22:30
SINGAPORE (UTC+8)



01:30 (WED)
SYDNEY (UTC+11)

Adjourn

WEDNESDAY, 24 NOVEMBER 2021

FORMERLY THE BIOMARKER MEETING OF PARIS
BIOMARKERS
of the Future



03:00 AM
NYC (UTC-5)



09:00
PARIS (UTC+1)



16:00
SINGAPORE (UTC+8)



19:00
SYDNEY (UTC+11)

SESSION 5 - HUMAN METABOLISM AND CARDIOVASCULAR DISEASE

Moderator: Roberto Latini - Mario Negri Institute (Milan, Italy)

Integrating proteomics with other omics for clinical insights

Claudia Langenberg - University of Cambridge

Cambridge, United Kingdom

Metabolomics in Cardiovascular disease

Deborah Novelli - Mario Negri Institute for Pharmacological Research

Milan, Italy

Omics in the follow-up of heart failure patients

Isabella Kardys - Erasmus University Medical Centre

Rotterdam, Netherlands

Self-assessment of capillary blood potassium by CKD and/or HF patients

Maurice Berenger - Cardio Renal

Paris, France

Panel discussion

Break



04:30 AM
NYC (UTC-5)



10:30
PARIS (UTC+1)



17:30
SINGAPORE (UTC+8)



20:30
SYDNEY (UTC+11)

SESSION 6 - NOVELTIES IN OMICS

Moderator: Antoni Bayes-Genis - Institut del Cor (Barcelona, Spain)

Molecular insights into sepsis: what we can learn from Onco-Omics approaches

Sabri Soussi - University of Toronto

Toronto, Canada

Next generation plasma proteome profiling

Mathias Uhlén - Royal Institute of Technology

Stockholm, Sweden

Use of omics in COVID-19 patients

Peter Pickkers - Radboud University Medical Center

Nijmegen, Netherlands

Circulatory protein biomarkers predict response to cancer immunotherapy and provide mechanistic insights into biology of resistance

Marijana Rucevic - Olink Proteomics

Boston, USA

Panel discussion

WEDNESDAY, 24 NOVEMBER 2021 (CONTINUED)

FORMERLY THE BIOMARKER MEETING OF PARIS
BIOMARKERS
of the Future



6:00 AM
NYC (UTC-5)



12:00
PARIS (UTC+1)



19:00
SINGAPORE (UTC+8)



22:00
SYDNEY (UTC+11)

YOUNG FELLOWS COMPETITION - PART I

Elevated plasma Galectin-3 is associated with Major Adverse Kidney events and death after ICU admission
Louis Boutin - University of Paris Paris, France

A systems-approach on plasma proteomics reveals the implication of KITLG signaling in critical COVID-19
George Gavriilidis - University of Ioannina Thessaloniki, Greece

No Title
Rafael Stroggilos - Academy of Athens Athens, Greece

Longitudinal proteomic profiling of end-stage kidney disease patients with COVID-19 reveals markers of severity and predictors of death
Jack Gisby - Imperial College London London, UK

Break



7:15 AM
NYC (UTC-5)



13:15
PARIS (UTC+1)



20:15
SINGAPORE (UTC+8)



23:15 (THU)
SYDNEY (UTC+11)

YOUNG FELLOWS COMPETITION

Ultrasound responsive polymer Microbubble for an efficient targeted treatment of thrombotic diseases
Louise Fournier - University of Paris Paris, France

High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis
Alberto Aimo - Scuola Superior Sant'Anna Pisa, Italy

Neurotensin and adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention
Maximilian Tscharre - University of Wiener Neustadt Vienna, Austria

GDF-15 together with NT-proBNP identify heart failure patients with reduced or mildly reduced ejection fraction at high risk of death, heart transplantation, or LVAD implantation
Vladimir Jakubo - University hospital Brno Brno, Czech Republic



7:59 AM
NYC (UTC-5)



13:59
PARIS (UTC+1)



20:59
SINGAPORE (UTC+8)



23:59 (THU)
SYDNEY (UTC+11)

SESSION 7 - REGIONAL DIFFERENCES ACROSS THE GLOBE

Moderator: Alexandre Mebazaa - University of Paris (Paris, France)

A multi-omics approach to decipher the pathophysiology of HFpEF
Jasper Tromp - National University of Singapore Singapore, Singapore

First in line for natriuretic peptides: homage to Paulo Bettencourt
Joao Ferreira - University of Porto Porto, Portugal

Panel discussion



9:00 AM
NYC (UTC-5)



15:00
PARIS (UTC+1)



22:00
SINGAPORE (UTC+8)



01:00 (THU)
SYDNEY (UTC+11)

YOUNG FELLOWS COMPETITION - PART III

In-depth proteomic characterisation of different aetiologies of cardiomyopathy

Claire Tonry - Queen's University Belfast

Belfast, UK

For or Towards the use of new generations of biomarkers for the early diagnosis of neonatal bacterial infections

Najah fatou Coly - University of Thiès Medical School

Dakar, Senegal

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) in patients with suspected functionally relevant coronary artery disease

Melissa Amrein - University Hospital of Basel

Basel, Switzerland

Metabolic profile of subjects with severe obesity: the influence of sex and age on the metabolome interplay with hormones in metabolic syndrome

Serena Pisoni - University of Valencia

Valencia, Spain

Break & Jury voting

Update of 2020 competition winner

Nicholas Cauwenberghs - University of Louvain

Leuven, Belgium

Awarding of prizes



10:25 AM
NYC (UTC-5)



16:25
PARIS (UTC+1)



23:25
SINGAPORE (UTC+8)



02:25 (THU)
SYDNEY (UTC+11)

Closing words & adjourn

NOTE TO SPEAKERS

Presentations are 12 minutes long, they will be pre-recorded and played during the conference. At the end of the session, you are invited to participate in a live panel discussion with the moderator and other speakers of the session.

NOTE TO YOUNG RESEARCHERS

Presentations are 7 minutes long, they will be pre-recorded and played during the conference and will be followed by 4 minutes of live discussion with the jury.

FORMERLY THE BIOMARKER MEETING OF PARIS

BIOMARKERS

of the Future

FROM BEDSIDE TO PRACTICE

VIRTUAL CONFERENCE · 23-24 NOVEMBER 2021

WWW.BIOMARKERSOFTHEFUTURE.COM



WITH THE SUPPORT OF

